期刊
CLINICAL CANCER RESEARCH
卷 28, 期 6, 页码 1180-1191出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-3017
关键词
-
类别
资金
- Medical Research Council Clinical Research Training Fellowship [MR/P001564/1]
- NIHR Biomedical Research Centre (BRC) at the Royal Marsden and the ICR [W94500]
- Breast Cancer Now [CTR-Q4-Y1-5, CTR-Q5-Y1]
- Breast Cancer Now Research Unit at Kings College London [KCL-Q2-Y1-5, KCL-Q3-Y1]
- Cancer Research UK Centre Grant [CRUK RE15196-9]
This study uses ultra-low-pass whole genome sequencing (ulpWGS) to analyze cell-free DNA in cerebrospinal fluid and plasma, aiming to evaluate its potential in the diagnosis and therapy response monitoring of breast cancer leptomeningeal metastasis (BCLM). The results show that the level of ctDNA is highly consistent with the mutant allele fraction measured by tumor mutation-specific ddPCR assays, and monitoring the changes in ctDNA can predict the survival and clinical progression of BCLM.
Purpose: Cerebrospinal fluid (CU) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or refute diagnosis. Further, there is no quantitative response tool to assess response or progression during BCLM treatment. Experimental Design: Facing the challenge of working with small-volume samples and the lack of common recurrent mutations in breast cancers, cell-free DNA was extracted from the CSF and plasma of patients undergoing investigation for BCLM (n = 30). ctDNA fraction was assessed by ultra-low-pass whole genome sequencing (ulpWGS), which does not require prior tumor sequencing. Results: In this proof-of-concept study, ctDNA was detected (fraction >= 0.10) in the CSF of all 24 patients with BCLM+ (median ctDNA fraction, 0.57), regardless of negative cytology or borderline MRI imaging, whereas CSF ctDNA was not detected in the six patients with BCLM- (median ctDNA fraction 0.03, P < 0.0001). Plasma ctDNA was only detected in patients with extracranial disease progression or who had previously received whole brain radiotherapy. ctDNA fraction was highly concordant with mutant allele fraction measured by tumor mutation-specific ddPCR assays (r = 0.852; P < 0.0001). During intrathecal treatment, serial monitoring (n = 12 patients) showed that suppression of CSF ctDNA fraction was associated with longer BCLM survival (P = 0.034), and rising ctDNA fraction was detectable up to 12 weeks before clinical progression. Conclusions: Measuring ctDNA fraction by ulpWGS is a quantitative marker demonstrating potential for timely and accurate BCLM diagnosis and therapy response monitoring, with the ultimate aim to improve management of this poor-prognosis patient group.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据